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Table 1: Molar volume (V) and Hansen partial solubility parameters (δDE, δPE and δHE) of 
the various potential elutants forming the domain from which the experimental elutants 
were selected [36-38]. 
Elutant 
number 
Elutant V (m3.mol-1) δDE (MPa1/2) δPE (MPa1/2) δHE (MPa1/2) 
1 Hexane 1.32  10-4 14.81 0.0 0.0 
2 Heptane 1.47  10-4 15.18 0.0 0.0 
3 Octane 1.64  10-4 15.45 0.0 0.0 
4 Nonane 1.80  10-4 15.65 0.0 0.0 
5 Decane 1.96  10-4 15.80 0.0 0.0 
6 Cyclohexane 1.09  10-4 16.74 0.0 0.0 
7 1,4-dioxane 8.60  10-5 19.03 1.8 7.4 
8 Acetone 7.40  10-5 15.51 10.4 7.0 
9 Acetonitrile 5.26  10-5 15.35 18.0 6.1 
10 Chloroform 8.10  10-5 17.70 3.1 5.7 
11 Ethyl acetate 9.80  10-5 15.22 5.3 9.2 
12 Toluene 1.07  10-4 18.01 1.4 2.1 
 




(µm ± SD) 
d50 
(µm ± SD) 
d90 
(µm ± SD) 
True density 
(g.cm-3 ± SD) 
Beclometasone 
dipropionate 
0.63 ± 0.00 1.25 ± 0.02 2.63 ± 0.05 1.357 ± 0.011 
Budesonide 0.67 ± 0.00 1.59 ± 0.01 4.04 ± 0.04 1.292 ± 0.006 
Salbutamol 
sulphate 
0.67 ± 0.00 1.50 ± 0.01 3.31 ± 0.01 1.334 ± 0.002 
Terbutaline 
sulphate 
0.71 ± 0.00 1.98 ± 0.02 5.50 ± 0.03 1.346 ± 0.002 
Triamcinolone 
acetonide 
1.16 ± 0.04 3.29 ± 0.13 6.59 ± 0.22 1.333 ± 0.072 
Erythritol 9.82 ± 0.28 79.33 ± 0.78 128.55 ± 2.12 1.446 ± 0.001 
Lactose 
monohydrate 
52.36 ± 0.96 97.12 ± 0.89 152.21 ± 1.36 1.541 ± 0.027 
Mannitol 6.97 ± 0.23 74.48 ± 1.53 138.16 ± 2.95 1.490 ± 0.001 
 
 
Table 3: Probable polymorph and dominant face Miller index of extremely smooth crystal 
substrates used for colloidal probe AFM adhesion and cohesion measurements. 
Material and Polymorph Dominant Face 
Beclometasone dipropionate anhydrate {110} 
Budesonide {002} 
Salbutamol sulphate {200} or {002} 
Terbutaline sulphate anhydrate (form B) {001} or {011} 
Triamcinolone acetonide (form I) {110}, {120} or {210} 
Erythritol {020} or {200} 
α-lactose monohydrate {100} 
D-mannitol (β polymorph) {002} 
 
Table 4: AFM CAB ratios ± SD and respective coefficients of determination (R2) for each 
drug-carrier interaction. 
AFM CAB ratio ± SD 
(R2) 
Erythritol Lactose Mannitol 
Beclometasone dipropionate 
0.51 ± 0.05 
(0.91) 
0.74 ± 0.04 
(0.97) 
0.69 ± 0.05 
(0.97) 
Budesonide 
1.38 ± 0.01 
(1.00) 
0.91 ± 0.03 
(0.99) 
0.95 ± 0.03 
(0.99) 
Salbutamol sulphate 
1.03 ± 0.05 
(0.95) 
0.72 ± 0.02 
(0.99) 
1.04 ± 0.03 
(0.99) 
Terbutaline sulphate 
1.09 ± 0.03 
(0.98) 
0.72 ± 0.03 
(0.96) 
0.98 ± 0.03 
(0.98) 
Triamcinolone acetonide 
1.15 ± 0.03 
(0.99) 
0.89 ± 0.03 
(0.99) 




Table 5: Results of matrix optimisation calculations used to determine the best 




(numbers from Table 1) 
D-optimality Variance inflation factors 
|X'X| |M| f(δDEi) f(δPEi) f(δHEi) 
4 5, 6, 9 & 11 1.044  1016 1.631  1014 3.391 3.731 1.457 
5 5, 6, 7, 9 & 11 2.225  1016 1.780  1014 2.927 2.706 1.319 
6 1, 5, 6, 7, 9 & 11 3.729  1016 1.726  1014 2.591 2.632 1.375 
7 1, 4, 5, 6, 7, 9 & 11 6.026  1016 1.757  1014 2.785 2.721 1.511 
8 1, 4, 5, 6, 7, 8, 9 & 11 9.095  1016 1.776  1014 3.193 3.118 3.193 
9 1, 4, 5, 6, 7, 8, 9, 10 & 11 1.203  1017 1.651  1014 2.978 2.764 1.625 
 
Table 6: Hansen partial solubility parameters determined for the eight study materials and 













18.2 ± 1.5 13.2 ± 2.6 8.1 ± 4.8 0.9985 
Budesonide 18.9 ± 2.9 10.5 ± 5.0 13.0 ± 9.1 0.9950 
Salbutamol sulphate 17.6 ± 2.5 11.1 ± 4.4 11.0 ± 8.0 0.9415 
Terbutaline sulphate 21.9 ± 10.3 13.8 ± 18.0 55.0 ± 32.7 0.8823 
Triamcinolone 
acetonide 
18.5 ± 1.2 3.0 ± 4.5 25.6 ± 4.7 0.9832 
Erythritol 12.9 ± 2.3 7.7 ± 4.1 16.9 ± 7.4 0.9486 
Lactose 14.3 ± 2.9 12.6 ± 5.0 18.8 ± 9.0 0.9554 
Mannitol 17.1 ± 3.6 3.6 ± 6.2 14.4 ± 11.3 0.8465 
 
 
Table 7: Relative strength of interparticulate interactions between each model drug and 
either itself (cohesion) or each of the model carrier excipients, as calculated from their 










142.9 107.5 145.7 120.9 
Budesonide 158.9 110.7 155.9 123.9 
Salbutamol sulphate 138.1 106.1 145.1 118.1 
Terbutaline sulphate 924.1 55.5 127.4 62.7 
Triamcinolone 
acetonide 
251.5 104.7 192.3 113.9 
 
 
Table 8: IGC CAB ratios for each drug-carrier interaction, as calculated from Hansen 
partial solubility parameters. 
 Erythritol Lactose Mannitol 
Beclometasone dipropionate 1.33 0.98 1.18 
Budesonide 1.44 1.02 1.28 
Salbutamol sulphate 1.30 0.95 1.17 
Terbutaline sulphate 16.65 7.25 14.74 
Triamcinolone acetonide 2.40 1.31 2.21 
 
